Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Curated Accruing

Recruiting interventional studies whose public record uses ctDNA or MRD to guide treatment, or lists it as a primary endpoint. 110 studies from 454 registry hits. Last synced Nov 14, 2026, 9:51 PM EST.

BreastNot applicableNCT07214532
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Natera, Inc. · 50 locations · Updated 2026-11-05
BreastNot applicableNCT05058183
Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer
Royal Marsden NHS Foundation Trust · 13 locations · Updated 2026-10-29
BreastPhase 2NCT06992336
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 locations · Updated 2026-10-23
BreastPhase 2NCT06923527
Circulating Tumor DNA
Yale University · 7 locations · Updated 2026-09-21
BreastPhase 2NCT07459673
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Memorial Sloan Kettering Cancer Center · 7 locations · Updated 2026-08-20
BreastPhase 2NCT07366112
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
Peking University People's Hospital · 1 locations · Updated 2026-07-13
BreastPhase 2NCT06970912
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Peking University People's Hospital · 1 locations · Updated 2026-07-13
BreastPhase 2NCT07394218
ctDNA-guided Treatment Decision-making
Fudan University · 1 locations · Updated 2026-02-06
BreastNot applicableNCT05658172
Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer
Prof. Wolfgang Janni · 1 locations · Updated 2025-05-02
BreastPhase 2NCT07069595
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
UNC Lineberger Comprehensive Cancer Center · 2 locations · Updated 2026-11-13
BreastPhase 2NCT05388149
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
University Health Network, Toronto · 1 locations · Updated 2026-10-13
BreastNot applicableNCT07025785
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
UNC Lineberger Comprehensive Cancer Center · 1 locations · Updated 2026-09-02
BreastPhase 2NCT06067503
Biomarkers to Detect Endocrine Therapy Resistance
University of Wisconsin, Madison · 1 locations · Updated 2026-08-25
BreastPhase 2NCT07191717
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial
Jonsson Comprehensive Cancer Center · 1 locations · Updated 2026-08-20
BreastPhase 2NCT07631052
Capecitabine in ER+/HER2-negative Breast Cancer
University Health Network, Toronto · 1 locations · Updated 2026-08-18
BreastPhase 2NCT04768426
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Stanford University · 1 locations · Updated 2026-08-12
BreastPhase 2NCT05770531
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
Vanderbilt-Ingram Cancer Center · 1 locations · Updated 2026-06-24
BreastPhase 2NCT07335081
ctDNA in HER2+ EBC Neoadjuvant Treatment
Shanghai Jiao Tong University School of Medicine · 1 locations · Updated 2026-03-24
BreastPhase 2NCT06517212
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Baylor Research Institute · 1 locations · Updated 2026-02-12
BreastPhase 2NCT06535893
Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer
Nagoya City University · 1 locations · Updated 2025-11-20
BreastPhase 2NCT03740893
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Institute of Cancer Research, United Kingdom · 6 locations · Updated 2025-08-11
BreastPhase 3NCT06643585
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
Prof. Wolfgang Janni · 1 locations · Updated 2025-05-02
BreastPhase 2NCT04985266
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
Royal Marsden NHS Foundation Trust · 49 locations · Updated 2024-12-05

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Circulating Tumor DNA

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

ctDNA-guided Treatment Decision-making

Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer

Biomarkers to Detect Endocrine Therapy Resistance

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Capecitabine in ER+/HER2-negative Breast Cancer

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

ctDNA in HER2+ EBC Neoadjuvant Treatment

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer

PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer

A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer